EDAP seeks US trials of prostate treatment:
This article was originally published in Clinica
EDAP TMS has asked the FDA for permission to begin human clinical trials of its new minimally-invasive, ultrasound-based ablation treatment for prostate cancer. The Ablatherm device uses a focused ultrasound beam to destroy well-defined tumours without affecting the surrounding tissue. The device, which is currently being used to treat localised prostate cancer in a multi-centre European study, has already been used to treat over 300 patients with successful results, said the Vaulx-en-Velin, France-based company.
You may also be interested in...
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.